U.S. Water Utilities Stock News

If you are looking at Qorvo and wondering whether the current share price reflects fair value or an opportunity, you are not alone. The stock last closed at US$79.85, with returns of a 0.5% decline over 7 days, a 6.8% decline over 30 days, a 7.4% decline year to date and an 8.8% decline over 1 year, alongside longer term returns of a 26.1% decline over 3 years and a 54.4% decline over 5 years. Recent attention on Qorvo has centered on how these share price moves fit with its position in the...

Option Care Health (OPCH) has drawn fresh attention after expanding its share repurchase authorization to US$1b, completing earlier buybacks, and issuing full year 2026 net revenue guidance of US$5.8b to US$6.0b. See our latest analysis for Option Care Health. Those announcements come after a strong run in the share price, with a 30 day share price return of 10.09% and a 90 day share price return of 26.51%, while the 1 year total shareholder return of 21.45% and 5 year total shareholder...

Earlier this month, National Vision Holdings, Inc. reaffirmed its earnings guidance for the 53 weeks ended January 3, 2026, maintaining expected net revenue between US$1.97 billions and US$1.99 billions. This confirmation of the revenue outlook reinforces management’s confidence in the company’s operating trajectory and offers investors increased clarity on near-term expectations. Next, we’ll examine how National Vision’s decision to reaffirm full-year earnings guidance shapes the company’s...

As the United States market experiences a rebound following recent volatility, with major indices like the Dow Jones and S&P 500 showing significant gains after addressing geopolitical tensions, investors are keeping a close eye on high-growth sectors. In this dynamic environment, identifying tech stocks with strong fundamentals and innovative potential can be crucial for navigating the opportunities presented by such market fluctuations.

Amid recent volatility in the U.S. markets, with major indices like the Dow Jones and S&P 500 experiencing significant fluctuations due to geopolitical tensions and economic policy shifts, investors are keenly observing opportunities that may arise from these movements. In such an environment, identifying stocks that are potentially undervalued based on intrinsic value estimates can offer a strategic advantage, as they might provide growth potential when market conditions stabilize.

Major stock indexes saw a significant rebound recently, with the Dow Jones adding 450 points after President Trump ruled out the use of force in Greenland. Amidst this backdrop of market volatility and geopolitical tensions, investors are exploring opportunities beyond traditional stocks. Penny stocks, often representing smaller or newer companies, continue to attract attention for their potential value and growth prospects. In this article, we explore three penny stocks that showcase...

Corvus Pharmaceuticals recently reported positive results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of oral soquelitinib in moderate to severe atopic dermatitis, and confirmed plans to start a Phase 2 study in the first quarter of 2026. The cohort 4 data are particularly interesting because they show clinical activity in patients who had previously failed systemic treatments, including dupilumab and JAK inhibitors, while maintaining a favorable safety profile...

Reverse split reshapes Ozop Energy Solutions share structure Ozop Energy Solutions (OZSC) is carrying out a 1 for 5,000 reverse stock split effective January 21, 2026. This move sharply consolidates its share count and changes the trading price per share. This type of corporate action does not alter the company’s reported revenue of US$0.32 million or its loss of US$6.95 million, but it can influence liquidity, trading behavior, and how different investors view the stock. See our latest...

Omega Healthcare Investors (NYSE:OHI) is showing a strong technical breakout pattern, pointing to renewed investor interest in the healthcare REIT space. The breakout aligns with a confirmed uptrend and a solid technical setup that traders may use as a rule-based entry signal. With shares last closing at $45.04, the move is drawing fresh attention from investors watching healthcare focused real estate names. For context, Omega Healthcare Investors has delivered a 28.1% return over the past...

If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place. The stock is modestly positive over 1 year with a 5.7% return, but has seen shorter term pullbacks with a 2.5% decline over 7 days and a 3.4% decline over 30 days, while the 3 and 5 year figures sit at 14.2% and 15.7% respectively. Recent headlines around Abbott Laboratories have focused on its position in medical devices and diagnostics, as...

If you are wondering whether Origin Bancorp's current share price reflects solid value or hidden risk, it helps to start by lining up the recent performance with what you are actually paying for the business. The stock last closed at US$39.70, with returns of 1.1% over 7 days, 2.1% over 30 days, 5.5% year to date, 13.1% over 1 year, 8.7% over 3 years, and 47.1% over 5 years. This gives useful context before comparing the price to fundamentals. Recent coverage has focused on Origin Bancorp's...

If you are trying to figure out whether Bilibili is attractively priced today, the key question is whether the recent share price reflects its underlying fundamentals or leaves room for value. Bilibili last closed at US$30.27, with a 7 day return of 3.6% decline, a 30 day return of 22.2% and a 1 year return of 77.5%, which sits alongside a 3 year return of 18.1% and a 5 year return of 76.0% decline. These moves sit against ongoing investor focus on Chinese tech and media names, where risk...

Gap Inc. (NYSE:GAP) has created a new Chief Entertainment Officer role and appointed Pam Kaufman. The company is launching a "Fashiontainment" approach that connects its brands more closely with entertainment and media. Gap is establishing an entertainment focused hub in Los Angeles to anchor content, partnerships, and collaborations. The first major licensing effort under this push is the Artist Series, featuring Robert Indiana's LOVE artwork. Gap Inc. (NYSE:GAP) is known for its core...

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Rivulet Entertainment (OTCPK:RIVF) opened 2026 with a quiet top line and a deeper loss, reporting Q1 total revenue of US$0 and a net loss of US$0.97 million, which translated to basic EPS of US$0.01. Over recent quarters the company has seen revenue move between US$0 and US$10 million, while quarterly basic EPS ranged from about US$0.00 to US$0.03 in losses. This sets a backdrop where margin pressure rather than sales growth is front and center for investors parsing this update. See our full...

If you are wondering whether PACS Group still offers good value after its strong run, or if most of the opportunity is already reflected in the share price, this article is designed to help you make sense of where the stock stands today. The share price closed at US$35.69, with a 15.3% decline over the last 7 days and a 1.9% decline over 30 days, but a 155.7% return over the past year suggests that the story has been far from quiet. Recent coverage has focused on PACS Group as a listed...

If you are wondering whether Ryman Hospitality Properties is attractively priced at around US$93.48, the key question is how that share price compares with what the business might reasonably be worth. The stock has seen mixed returns, with a 1% decline over the past week, a 4.6% decline over the past month, a 2.1% decline year to date, but gains of 21.1% over three years and 68.3% over five years, which can change how investors think about both upside potential and risk. Recent coverage has...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

If you are wondering whether Novavax's share price still reflects its true worth, you are not alone. This article will walk through what the current valuation really says. Over the past month the stock is up 23.1%, even though the 7 day return is a 5.4% decline and the 1 year return sits at a 6.9% loss after much steeper falls of 29.0% over 3 years and 93.6% over 5 years. Recent moves in Novavax shares have been framed by ongoing interest in vaccine related companies and renewed investor...

Why REV Group is on investors’ radar today REV Group (REVG) has drawn fresh attention after recent trading left the stock with mixed short term returns but stronger gains over the month and past 3 months, prompting investors to reassess its valuation. See our latest analysis for REV Group. Despite a 2.1% one-day share price decline and some recent softness over the past week, REV Group’s 30-day share price return of 8.4% and very large 5-year total shareholder return suggest longer-term...

If you are wondering whether ServisFirst Bancshares at around US$76.33 is offering good value right now, you are not alone. This article is set up to help you make sense of that question. The stock has returned 1.6% over the past week and 5.1% over the last 30 days, while the 1 year return of negative 13.6% contrasts with longer term gains of 24.6% over 3 years and 89.1% over 5 years. Recent attention on regional banks, and ServisFirst Bancshares in particular, has centered on how investors...

Elastic (NYSE:ESTC) has rolled out an upgraded Elastic Cloud Serverless platform on Amazon Web Services. The release introduces higher indexing throughput and lower search latency through the use of AWS Graviton instances. The upgrade is live immediately for all AWS based serverless users, with no manual changes required. The company highlights benefits for search, observability, and AI/ML workloads that rely on larger and more complex data volumes. For context, Elastic focuses on search,...

In January 2026, Tenaya Therapeutics outlined past and upcoming 2026 milestones for its TN-201 and TN-401 gene therapy programs, including interim MyPEAK-1 data, additional RIDGE-1 updates, and plans to seek regulatory alignment on potential pivotal studies. A key insight is that both programs target genetically defined cardiac conditions with U.S. FDA designations and planned data readouts that could clarify each therapy’s clinical risk profile and development path. We will now examine how...

If you are trying to work out whether Axcelis Technologies is still a reasonable entry point or already pricing in a lot of good news, its current valuation story is worth a closer look. The share price recently closed at US$88.16, with returns of 6.6% over the last 30 days and 23.4% over the last year, although the stock has seen a 9.2% decline over the past week and an 18.3% decline over three years, with a 135.5% gain over five years and a 2.4% return year to date. Recent coverage has...